New vaccine aims to stop pancreatic cancer return
NCT ID NCT07612930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers a personalized vaccine called PCNAT-01 to patients with pancreatic cancer who have had surgery and finished chemotherapy. The vaccine is made from each patient's unique tumor proteins and is given as shots to train the immune system to fight any remaining cancer cells. The goal is to lower the chance of the cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PCNAT-01 (personalized tumor neoantigen peptide vaccine with Poly-ICLC)
- What this could lead to
- If it works, this could help prevent pancreatic cancer from coming back after surgery and chemotherapy.
- What could go wrong
- This is an early expanded access program, not a full trial, so results are uncertain. The vaccine is personalized and may not work for everyone, and there are risks like side effects from the injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer